Bone Matrix Proteoglycans in Skeletal Function - Osteogenesis Imperfecta - page 86

[55] Alini M, Roughley PJ. Changes in leucine-rich repeat proteo-
glycans during maturation of the bovine growth plate. Matrix
Biol 2001;19(8):805-13.
[56] Jepsen KJ, Wu F, Peragallo JH, Paul J, Roberts L, Ezura Y,
et al. A syndrome of joint laxity and impaired tendon integ-
rity in lumican- and ibromodulin-deicient mice. J Biol Chem
2002;277(38):35532-40.
[57] Chakravarti S, Magnuson T. Localization of mouse lumican
(keratan sulfate proteoglycan) to distal chromosome 10. Mamm
Genome 1995;6(5):367-8.
[58] Chakravarti S, Stallings RL, SundarRaj N, Cornuet PK,
Hassell JR. Primary structure of human lumican (keratan sul-
fate proteoglycan) and localization of the gene (LUM) to chro-
mosome 12q21.3-q22. Genomics 1995;27(3):481-8.
[59] Svensson L, Narlid I, Oldberg A. Fibromodulin and lumican
bind to the same region on collagen type I ibrils. FEBS Lett
2000;470(2):178-82.
[60] Gori F, Schipani E, Demay MB. Fibromodulin is expressed by
both chondrocytes and osteoblasts during fetal bone develop-
ment. J Cell Biochem 2001;82(1):46-57.
[61] Saamanen AM, Salminen HJ, Rantakokko AJ, Heinegard D,
Vuorio EI. Murine ibromodulin: cDNA and genomic structure,
and age-related expression and distribution in the knee joint.
Biochem J 2001;355(Pt 3):577-85.
[62] Goldberg M, Ono M, Septier D, Bonnefoix M, Kilts TM, Bi Y,
et al. Fibromodulin-deicient mice reveal dual functions for
ibromodulin in regulating dental tissue and alveolar bone for-
mation. Cells Tissues Organs 2009;189(1-4):198-202.
[63] Raouf A, Seth A. Discovery of osteoblast-associated genes
using cDNA microarrays. Bone 2002;30(3):463-71.
[64] Chakravarti S. Functions of lumican and ibromodulin: lessons
from knockout mice. Glycoconj J 2002;19(4-5):287-93.
[65] Grover J, Chen XN, Korenberg JR, Recklies AD, Roughley PJ.
The gene organization, chromosome location, and expression
of a 55-kDa matrix protein (PRELP) of human articular carti-
lage. Genomics 1996;38(2):109-17.
[66] Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A,
Ahrman E, et al. The glycosaminoglycan-binding domain of
PRELP acts as a cell type-speciic NF-kappaB inhibitor that
impairs osteoclastogenesis. J Cell Biol 2009;187(5):669-83.
[67] Iozzo RV, Naso MF, Cannizzaro LA, Wasmuth JJ,
McPherson JD. Mapping of the versican proteoglycan gene
(CSPG2) to the long arm of human chromosome 5 (5q12-5q14).
Genomics 1992;14(4):845-51.
[68] Dours-Zimmermann MT, Zimmermann DR. A novel gly-
cosaminoglycan attachment domain identiied in two
alternative splice variants of human versican. J Biol Chem
1994;269(52):32992-98.
[69] Bode-Lesniewska B, Dours-Zimmermann MT, Odermatt BF,
Briner J, Heitz PU, Zimmermann DR. Distribution of the large
aggregating proteoglycan versican in adult human tissues.
J Histochem Cytochem 1996;44(4):303-12.
[70] Robey PG. Vertebrate mineralized matrix proteins: structure
and function. Connect Tissue Res 1996;35(1-4):131-6.
[71] Nakamura M, Sone S, Takahashi I, Mizoguchi I, Echigo S,
Sasano Y. Expression of versican and ADAMTS1, 4, and 5
during bone development in the rat mandible and hind limb.
J Histochem Cytochem 2005;53(12):1553-62.
[72] Foster LJ, Zeemann PA, Li C, Mann M, Jensen ON, Kassem M.
Differential expression proiling of membrane proteins by quan-
titative proteomics in a human mesenchymal stem cell line under-
going osteoblast differentiation. Stem Cells 2005;23(9):1367-77.
[73] Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P,
Gehron Robey P. Fibrous dysplasia of bone in the McCune-
Albright syndrome: abnormalities in bone formation. Am J
Pathol 1997;151(6):1587-600.

[74] Korenberg JR, Chen XN, Doege K, Grover J, Roughley PJ.
Assignment of the human aggrecan gene (AGC1) to 15q26
using luorescence in situ hybridization analysis. Genomics
1993;16(2):546-8.
[75] Doege KJ, Sasaki M, Kimura T, Yamada Y. Complete coding
sequence and deduced primary structure of the human carti-
lage large aggregating proteoglycan, aggrecan. Human-speciic
repeats, and additional alternatively spliced forms. J Biol Chem
1991;266(2):894-902.
[76] Day JM, Olin AI, Murdoch AD, Canield A, Sasaki T, Timpl R,
et al. Alternative splicing in the aggrecan G3 domain inluences
binding interactions with tenascin-C and other extracellular
matrix proteins. J Biol Chem 2004;279(13):12511-18.
[77] Watanabe H, Nakata K, Kimata K, Nakanishi I, Yamada Y.
Dwarism and age-associated spinal degeneration of heterozy-
gote cmd mice defective in aggrecan. Proc Natl Acad Sci USA
1997;94(13):6943-7.
[78] Baldwin CT, Reginato AM, Prockop DJ. A new epidermal
growth factor-like domain in the human core protein for the
large cartilage-speciic proteoglycan. Evidence for alternative
splicing of the domain. J Biol Chem 1989;264(27):15747-50.
[79] Wong M, Lawton T, Goetinck PF, Kuhn JL, Goldstein SA,
Bonadio J. Aggrecan core protein is expressed in membra-
nous bone of the chick embryo. Molecular and biomechani-
cal studies of normal and nanomelia embryos. J Biol Chem
1992;267(8):5592-8.
[80] Watanabe H, Kimata K, Line S, Strong D, Gao LY, Kozak CA,
et al. Mouse cartilage matrix deiciency (cmd) caused by a 7 bp
deletion in the aggrecan gene. Nat Genet 1994;7(2):154-7.
[81] Gleghorn L, Ramesar R, Beighton P, Wallis G. A mutation in the
variable repeat region of the aggrecan gene (AGC1) causes a
form of spondyloepiphyseal dysplasia associated with severe,
premature osteoarthritis. Am J Hum Genet 2005;77(3):484-90.
[82] Kallunki P, Eddy RL, Byers MG, Kestila M, Shows TB,
Tryggvason K. Cloning of human heparan sulfate proteoglycan
core protein, assignment of the gene (HSPG2) to 1p36.1-p35
and identiication of a BamHI restriction fragment length poly-
morphism. Genomics 1991;11(2):389-96.
[83] Wintle RF, Kisilevsky R, Noonan D, Duncan AM. In situ
hybridization to human chromosome 1 of a cDNA probe
for the gene encoding the basement membrane hepa-
ran sulfate proteoglycan (HSPG). Cytogenet Cell Genet
1990;54(1-2):60-1.
[84] Brown JC, Sasaki T, Gohring W, Yamada Y, Timpl R. The
C-terminal domain V of perlecan promotes beta1 integrin-
mediated cell adhesion, binds heparin, nidogen and ibulin-2
and can be modiied by glycosaminoglycans. Eur J Biochem
1997;250(1):39-46.
[85] Chan I. The role of extracellular matrix protein 1 in human
skin. Clin Exp Dermatol 2004;29(1):52-6.
[86] Govindraj P, West L, Koob TJ, Neame P, Doege K, Hassell JR.
Isolation and identiication of the major heparan sulfate pro-
teoglycans in the developing bovine rib growth plate. J Biol
Chem 2002;277(22):19461-69.
[87] Hecht JT, Hayes E, Haynes R, Cole WG, Long RJ, Farach-
Carson MC, et al. Differentiation-induced loss of heparan sul-
fate in human exostosis derived chondrocytes. Differentiation
2005;73(5):212-21.
[88] Handler M, Yurchenco PD, Iozzo RV. Developmental expres-
sion of perlecan during murine embryogenesis. Dev Dyn
1997;210(2):130-45.
[89] van Det NF, Tamsma JT, van den Born J, Verhagen NA, van den
Heuvel LP, Lowik CW, et al. Differential effects of angiotensin
II and transforming growth factor beta on the production of
heparan sulfate proteoglycan by mesangial cells in vitro. J Am
Soc Nephrol 1996;7(7):1015-23.